Côte d'Ivoire vs Lebanon: Share of the population living with HIV receiving antiretroviral therapy
Côte d'Ivoire
78.1%
in 2024
Lebanon
78.8%
in 2024
Côte d'Ivoire rank
57th
Lebanon rank
56th
Share of the population living with HIV receiving antiretroviral therapy over time
- Côte d'Ivoire
- Lebanon
How they compare
Lebanon currently reports 78.8% against 78.1% in Côte d'Ivoire, a difference of 0.7%.
Across all 35 years both countries report, Lebanon has been ahead every year.
Côte d'Ivoire ranks 57th and Lebanon ranks 56th of 149 countries.
Lebanon has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Côte d'Ivoire | Lebanon | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 4.0% | 18.4% | 14.4% | Lebanon |
| 2010s | 35.8% | 55.7% | 20.0% | Lebanon |
| 2020s | 71.3% | 80.5% | 9.1% | Lebanon |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Côte d'Ivoire or Lebanon?
- Lebanon, at 78.8% against 78.1% in Côte d'Ivoire as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Côte d'Ivoire and Lebanon?
- 0.7%, with Lebanon ahead.
- How many years of comparable data are there for Côte d'Ivoire and Lebanon?
- 35 years are reported by both, from 1990 to 2024.
- How do Côte d'Ivoire and Lebanon rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Côte d'Ivoire ranks 57th and Lebanon ranks 56th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.